Working party members and contributors

From Cancer Guidelines Wiki

Jump to: navigation, search

Guidelines commissioned by

Working party members and contributors

Working party member	Clinical questions
Annabel Pollard RN, BA, Grad. Dip App Psych, M Psych (Clinical) MAPS	What is the role of psychological support and interventions in the treatment of lung cancer? (body of evidence)— Co-author
Associate Professor Christos Karapetis	What is the role of chemotherapy after surgery in the treatment of operable stage I NSCLC? (body of evidence)— Author What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC? (body of evidence)— Author What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage I NSCLC? (body of evidence)— Author
Professor David Ball MB BS, MD, FRANCZR	What is the best practice radiotherapy approach in patients with stage I inoperable NSCLC? (body of evidence)— Author What is the best practice radiotherapy approach in patients with stage II inoperable NSCLC? (body of evidence)— Author What is the role of radiofrequency ablation in stage I inoperable NSCLC? (body of evidence)— Author What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC? (body of evidence)— Author What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC? (body of evidence)— Author What is the role of radiotherapy in the treatment of operable stage I NSCLC? (body of evidence)— Author
Di Saward	What is the role of palliative care in symptom management for patients with lung cancer? (body of evidence)— Co-author
Dr Dish Gunawardana	Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal second-line therapy in patients with stage IV inoperable NSCLC? (body of evidence)— Co-author Is carboplatin based chemotherapy as effective as cisplatin based chemotherapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author Is chemotherapy with a biologic or targeted therapy superior to chemotherapy alone in unselected patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal chemotherapy regimen for overall quality of life for patients in the treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal duration of first-line chemotherapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal first-line maintenance therapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal systemic therapy for stage IV inoperable NSCLC?/Historical evolution of systemic drug treatment for stage IV NSCLC (body of evidence)— Co-author What is the optimal systemic therapy regimen for elderly patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal systemic therapy regimen in selected patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal third-line therapy in unselected patients with stage IV inoperable NSCLC? (body of evidence)— Co-author Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? (body of evidence)— Co-author
Associate Professor Gavin Wright MD FRACS	Does complete mediastinal lymph node dissection improve overall survival compared to mediastinal lymph node staging in stage I NSCLC? (body of evidence)— Author Does complete mediastinal lymph node dissection improve overall survival compared to mediastinal lymph node staging in stage II NSCLC? (body of evidence)— Author Is minimally invasive lobectomy as effective as open lobectomy for treatment of operable stage I NSCLC? (body of evidence)— Author What is the clinical benefit of mediastinal lymph node dissection in stage IIIA operable NSCLC? (body of evidence)— Author
Dr Jeremy Ruben FCRadOnc(SA), FRANZCR, MMed	Is there a role for thoracic radiotherapy in patients with extensive stage SCLC? (body of evidence)— Author What is the optimal dose and fractionation schedule of prophylactic cranial irradiation in patients with extensive stage SCLC? (body of evidence)— Author What is the optimal dose and fractionation schedule of prophylactic cranial irradiation in patients with limited stage SCLC? (body of evidence)— Author What is the optimal dose and fractionation schedule of thoracic radiotherapy in patients with limited stage SCLC? (body of evidence)— Author What is the optimal timing of thoracic radiotherapy in patients receiving chemotherapy for limited stage SCLC? (body of evidence)— Author What is the optimal treatment volume in patients with limited stage SCLC receiving thoracic radiotherapy? (body of evidence)— Author Which patients with SCLC benefit from prophylactic cranial irradiation? (body of evidence)— Author
Associate Professor Josephine Clayton MBBS PhD FRACP FAChPM	What is the role of advance care planning and timing of referral for patients with lung cancer? (body of evidence)— Co-author What is the role of palliative care in symptom management for patients with lung cancer? (body of evidence)— Co-author What is the role of psychological support and interventions in the treatment of lung cancer? (body of evidence)— Co-author
Dr Margot Lehman MBBS FRANZCR GDP	What are the principles of radiation therapy in the definitive management of stage III inoperable NSCLC? (body of evidence)— Author What is the optimal management of Pancoast tumours? (body of evidence)— Author What is the optimal radiation dose and fractionation schedule for good performance status patients with inoperable stage III NSCLC undergoing curative therapy? (body of evidence)— Author What is the optimal treatment approach for patients with stage III inoperable NSCLC who, because of patient or tumour factors, are not suitable for curative treatment with concurrent chemo-radiotherapy? (body of evidence)— Author What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease? (body of evidence)— Author What is the role of postoperative radiotherapy (PORT) in resected stage III NSCLC? (body of evidence)— Author What is the role of prophylactic cranial irradiation in patients with stage III NSCLC? (body of evidence)— Author
Dr Maria Ftanou BAppSc(Hons) Dpsych Clinical	What is the role of psychological support and interventions in the treatment of lung cancer? (body of evidence)— Author
Prof Matthew Peters MD FRACP	What is the role of case management in the treatment of patients with lung cancer? (body of evidence)— Author What is the role of topical creams, skin moisturisers and maintenance antibiotics in the treatment of rash from anti-EGFR therapy in patients with lung cancer? (body of evidence)— Author What is the optimal management of malignant pleural effusions? (body of evidence)— Author
Professor Michael Brown MBBS PhD FRACP FRCPA	What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC? (body of evidence)— Author What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? (body of evidence)— Author
Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACP	What is the optimal chemotherapy regimen and duration of therapy in extensive stage small cell lung cancer in the first line setting? (body of evidence)— Author What is the optimal concurrent chemotherapy to be used for the treatment of limited stage small cell lung cancer with radiotherapy? (body of evidence)— Author What is the optimal second line therapy in patients with extensive stage small cell lung cancer? (body of evidence)— Author What is the optimal systemic therapy and duration to be used for the treatment of limited stage small cell lung cancer? (body of evidence)— Author
Mustafa Khasraw MBChB MD MRCP FRACP	Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal second-line therapy in patients with stage IV inoperable NSCLC? (body of evidence)— Co-author Is carboplatin based chemotherapy as effective as cisplatin based chemotherapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author Is chemotherapy with a biologic or targeted therapy superior to chemotherapy alone in unselected patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal chemotherapy regimen for overall quality of life for patients in the treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal duration of first-line chemotherapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal first-line maintenance therapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal systemic therapy for stage IV inoperable NSCLC?/Historical evolution of systemic drug treatment for stage IV NSCLC (body of evidence)— Co-author What is the optimal systemic therapy regimen for elderly patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal systemic therapy regimen in selected patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal third-line therapy in unselected patients with stage IV inoperable NSCLC? (body of evidence)— Co-author Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC? (body of evidence)— Co-author What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? (body of evidence)— Co-author
Dr Natasha Michael MBChB MRCP MRCGP MSC	What is the role of advance care planning and timing of referral for patients with lung cancer? (body of evidence)— Co-author What is the role of palliative care in symptom management for patients with lung cancer? (body of evidence)— Author What is the role of psychological support and interventions in the treatment of lung cancer? (body of evidence)— Co-author
Assoc. Prof. Nick Pavlakis	Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC? (body of evidence)— Author Are three chemotherapy agents better than two chemotherapy agents for treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal second-line therapy in patients with stage IV inoperable NSCLC? (body of evidence)— Author Is carboplatin based chemotherapy as effective as cisplatin based chemotherapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Author Is chemotherapy with a biologic or targeted therapy superior to chemotherapy alone in unselected patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Author Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal chemotherapy regimen for overall quality of life for patients in the treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal duration of first-line chemotherapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal first-line maintenance therapy for treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal systemic therapy for stage IV inoperable NSCLC?/Historical evolution of systemic drug treatment for stage IV NSCLC (body of evidence)— Author What is the optimal systemic therapy regimen for elderly patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal systemic therapy regimen in selected patients for treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal third-line therapy in unselected patients with stage IV inoperable NSCLC? (body of evidence)— Author Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC? (body of evidence)— Author What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? (body of evidence)— Author
Associate Professor Shalini Vinod MBBS MD FRANZCR	What is the clinical benefit of adjuvant whole brain radiotherapy following resection or stereotactic radiosurgery to the brain metastasis(es) (body of evidence)— Author What is the clinical benefit of radiotherapy in metastatic spinal cord compression? (body of evidence)— Author What is the clinical benefit of radiotherapy to the bone for metastatic disease from NSCLC? (body of evidence)— Author What is the clinical benefit of radiotherapy to the brain for patients with inoperable brain metastases from NSCLC? (body of evidence)— Author What is the clinical benefit of radiotherapy to the lung primary in Stage IV NSCLC? (body of evidence)— Author What is the role of stereotactic radiosurgery in the treatment of brain metastases? (body of evidence)— Author
Dr Shawgi Sukumaran	What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? (body of evidence)— Author What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? (body of evidence)— Author What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC? (body of evidence)— Author
Dr Stephen Barnett	What is the clinical benefit of resection of brain metastasis? (body of evidence)— Author What is the clinical benefit of resection of primary disease after complete resection of metastatic disease? (body of evidence)— Author What is the clinical benefit of the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy in stage IIIA (N2) NSCLC? (body of evidence)— Author What is the clinical benefit of the addition of surgery to definitive chemoradiotherapy in stage IIIA (N2) NSCLC? (body of evidence)— Author What is the optimal management of malignant pleural effusions? (body of evidence)— Author
Dr Tracy Smith BSc, MBBS, FRACP, Clin Dip Pall Med	What is the role of advance care planning and timing of referral for patients with lung cancer? (body of evidence)— Author

Name	Affiliation
Professor Kwun Fong MBBS, FRACP, PhD (Qld)	Working Party member, Thoracic and Sleep Physician at The Prince Charles Hospital, Brisbane, Professor with the School of Medicine at the University of Queensland
Associate Professor Jeff Garrett	Working Party member, Respiratory Physician, Middlemore Hospital, Auckland NZ
Ian Stubbin (NSW)	Consumer representative to the Working Party
Sandy Thomson (SA)	Consumer representative to the Working Party

Retrieved from "http://wiki.cancer.org.au/australia/Guidelines:Lung_cancer/Working_party_members_and_contributors"

• This page was last modified on 11 January 2013, at 16:48.

• Privacy policy
• About Cancer Guidelines Wiki
• Disclaimers